SPD503 (extended-release Guanfacine hydrochloride)
SPD503-210
Phase 2 small_molecule completed
Quick answer
SPD503 (extended-release Guanfacine hydrochloride) for Generalized Anxiety Disorder (GAD) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Generalized Anxiety Disorder (GAD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed